Finding Points to Possible New Parkinson’s Therapy

A new study shows that, when properly manipulated, a population of support cells found in the brain called astrocytes could provide a new and promising approach to treat Parkinson’s disease.  These findings, which were made using an animal model of the disease, demonstrate that a single therapy could simultaneously repair the multiple types of neurological damage caused by Parkinson’s, providing an overall benefit that has not been achieved in other approaches.
Read More

iCardiac Technologies Partners with Norwest Venture Partners to Accelerate Growth

Palo Alto, CA – March 6, 2014 — iCardiac Technologies, Inc., a leading global provider of cardiac safety assessment services, today announced a partnership transaction with Norwest Venture Partners (NVP), a global, multi-stage investment firm with $3.7 billion in capital under management. iCardiac will leverage the extensive strategic resources NVP has to offer to aggressively pursue significant growth opportunities and serve the rapidly growing needs of its pharmaceutical and medical device clients worldwide. Also as part of today’s announcement, two of NVP’s healthcare investment leaders, Dr. Ryan Harris and Dr. Robert Mittendorff, will join the Company’s board of directors.

The average cost to develop a new drug is about $1.2B and requires 10 to 15 years of development time.* iCardiac’s unique and proprietary technology allows CROs and pharmaceutical sponsors to obtain cardiac safety assessment results with less variance, resulting in smaller sample sizes and less development time. iCardiac is the world’s largest dedicated ECG core laboratory serving the pharmaceutical industry. It currently serves seven of the world’s 10 largest pharmaceutical companies, as well as numerous medium and small biotech, pharmaceutical and medical device clients.

–more–

SRO at UVANY Venture Forum

UVANY Forum March 2014

More than 150 entrepreneurs and venture capitalists from throughout New York State gathered at Brighton’s ARTISANworks Tuesday evening to network and to hear some Rochester success stories. Organized by the Upstate Venture Association of New York (UVANY), the event featured an introductory presentation on “The New Rochester” by Richard Glaser and an interactive panel discussion featuring Mike Totterman (iCardiac), David Chauncey (vNomics), Tim Wilson (Arnold Magnetics), and Chris Modesti (Biomaxx). The panel was moderated by Will Hoy (Secrest & Emery). The venue perfectly captured the energy and creativity present in the room. The picture, above, was taken seconds before the UR Ventures banner stand noisily imploded.

Dr. Nedergaard’s Sleep Research Receives Worldwide Attention

Everyone is talking about Dr. Nedergaard’s discovery. We can’t blame them. This has huge potential. But don’t take our word for it . . . .

io9:
http://bit.ly/1gOM5U3

Science Magazine:
http://bit.ly/1hU0D8N

NIH News Update:
http://1.usa.gov/1kuEP5b

Neuroscience News:
http://bit.ly/MKUAWP

NBC:
http://nbcnews.to/1bXANQb

BBC:
http://bbc.in/1dXojTM

NPR:
http://n.pr/1ddsU37

NY Times:
http://nyti.ms/KQMewd